Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer

NCT00003184 is registered in ClinicalTrials.gov with Providence Cancer Center, Earle A. Chiles Research Institute as lead sponsor.

NCT NCT00003184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer
Lead sponsor
Providence Cancer Center, Earle A. Chiles Research Institute
Phase
Phase 1
Overall status
Completed
Start date
August 31, 1996
Completion date
July 31, 2003
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer